Global Information
회사소개 | 문의 | 비교리스트

과거 10년간 감염증의 세계 유행

Pandemic Outbreaks in the Past Decade: A BCC Research Overview

리서치사 BCC Research
발행일 2020년 06월 상품 코드 940537
페이지 정보 영문 76 Pages
가격
US $ 3,950 ₩ 4,789,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 1회이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,740 ₩ 5,747,000 PDF by E-mail (2-5 Users) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 5회까지이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,688 ₩ 6,897,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,826 ₩ 8,277,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


과거 10년간 감염증의 세계 유행 Pandemic Outbreaks in the Past Decade: A BCC Research Overview
발행일 : 2020년 06월 페이지 정보 : 영문 76 Pages

과거 10년간 감염증의 세계 유행 사례를 조사했으며, 과거 주요 감염증 유행 사례와 병원 미생물, 발생 요인, 역학, 병태생리, 진단·평가법, 치료·관리법, 각국 및 국제적인 구상, 과거 세계 유행으로부터 배우는 교훈 등을 정리하여 전해드립니다.

제1장 서론

제2장 감염증의 세계 유행 : 서론

  • 병원 미생물과 감염증 : 1973-2019년
  • 감염증의 발생을 일으키는 요인
  • 바이러스 발생·유행·세계 유행의 분류
  • 현재 유행과 잠재성·세계 유행의 가능성
  • 현재 세계 유행과 잠재성
  • 현재의 대처 기술
  • 테러의 생물무기
  • 다음의 세계 유행
  • 인수공통 바이러스의 유형
  • 감염증의 세계 유행 : 과거 경위
  • 감염증의 치료

제3장 H1N1 인플루엔자(돼지 인플루엔자)

  • 병인
  • 역학
  • 병태생리
  • 인플루엔자 바이러스의 유형
    • 인플루엔자 바이러스 A
    • 인플루엔자 바이러스 B
    • 인플루엔자 바이러스 C
  • 진단·평가
  • 치료·관리
  • WHO와 봉쇄
  • 인플루엔자 백신 비축
  • 유행전 백신 접종
  • 항바이러스 내성
  • 재작성 바이러스
  • 무형의 시장 리스크
  • 미디어 보도와 백신 접종
  • 주요 국가의 대책 계획

제4장 에볼라 바이러스병

  • 병인
  • 역학
  • 임상 증상
  • 진단
  • 치료·관리

제5장 MERS(중동 호흡기 증후군)

  • 병인
  • 역학
  • 병태생리
  • 임상적 특징
  • 진단
  • 치료·관리
  • 방지
  • 우선사항 : MERS 연구·감시·관리·제어

제6장 신종 코로나바이러스 감염증(SARS-CoV-2)

  • COVID-19의 증상
  • COVID-19의 진행
  • 잠복 기간
  • 역학
  • R&D
  • 진단·Medtech
  • 인공호흡기를 재발명할 필요성
  • COVID-19의 임상시험

제7장 과거로부터 배우는 교훈

  • 필수 의료 서비스의 유지
  • 예방·안전 대책·검사·치료에 대한 액세스
  • 격리와 분리
  • 세계 발생 대책 시스템을 강화하기 위한 국제적 구상

제8장 부록

KSA 20.06.25

List of Tables

  • Table 1: Pathogenic Bacteria, Parasites and Viruses, 1973-2019
  • Table 2: History of Antibiotic Discovery and Approval, 1935-2013
  • Table 3: CDC: Six Phases of Classification of Viral Pandemics
  • Table 4: Technologies for Addressing Potential Pandemic Threats
  • Table 5: Diseases That Have Been or Can Be Weaponized
  • Table 6: Commercial Products of H1N1 Influenzas Diagnostics
  • Table 7: Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2017
  • Table 8: Essential and Desirable Elements of the WHO Influenza Pandemic Preparedness Plan
  • Table 9: Japan's Action Plan for Influenza Pandemic Preparedness
  • Table 10: China's Influenza Pandemic Warning Levels
  • Table 11: Brazil's Influenza Pandemic Warning Levels and Action
  • Table 12: Ebola Outbreaks Between 1976 and 2014
  • Table 13: Clinical Features of Ebola Virus Disease, by Stage
  • Table 14: Overview of Investigational Therapeutics Evaluated in Clinical Trials on Ebola Virus Disease During the 2013-2016 West African Outbreak
  • Table 15: Key Vaccines with Accelerated Clinical Development During the 2013-2016 Ebola Virus Disease Outbreak
  • Table 16: Molecular Diagnostic Tests for MERS-CoV Diagnosis, Single Assays
  • Table 17: Molecular Diagnostic Tests for MERS-CoV Diagnosis, Multiplex Assays
  • Table 18: Serology Tests for MERS-CoV Diagnosis
  • Table 19: Potential Therapies for MERS-CoV Infection
  • Table 20: Vaccines in the Pipeline for the Prevention of MERS-CoV Infection
  • Table 21: COVID-19 Symptoms by Percentage of Patients
  • Table 22: Case Fatality Rate of COVID-19, by Region, March 2020
  • Table 23: Case Fatality Rate of COVID-19, by Selected Country
  • Table 24: COVID-19: Confirmed Cases and Deaths, by Country, May 14, 2020
  • Table 25: COVID-19 Therapeutic Interventions in Development, by Biopharmaceutical Companies in Collaboration
  • Table 26: COVID-19 Therapeutics in Development, by Biopharmaceutical Company
  • Table 27: COVID-19 Vaccines in Development, by Biopharmaceutical Companies in Collaboration
  • Table 28: COVID-19 Vaccines in Development, by Biopharmaceutical Company
  • Table 29: Modifiable Breathing Devices Eligible for EUAs, by Company
  • Table 30: Number of Clinical Trials on COVID-19, by Phase
  • Table 31: Number of Clinical Trials on COVID-19, by Intervention
  • Table 32: Clinical Trials on COVID-19, by Country
  • Table 33: High-Level Initiatives Established Since the Ebola Crisis
  • Table 34: List of Acronyms

List of Figures

  • Figure 1: Number of Approved WHO Influenza Centers, by WHO Dedignated Region
  • Figure 2: Targeted Pre-pandemic Influenza Vaccine Stockpiles Based on Population Demand for Selected Countries
  • Figure 3: Geographical Distribution of Reported Human Infections of MERS-CoV
  • Figure 4: Infographic Comparison of CFR and Cases of the Three Major Beta Coronaviruses: MERS, SARS, and COVID-19
  • Figure 5: Distribution of Clinical Trials on COVID-19, by Phase
  • Figure 6: Distribution of Clinical Trials on COVID-19, by Intervention
  • Figure 7: Distribution of Clinical Trials on COVID-19, by Country
  • Figure 8: The Role of High-Level Initiatives in Enhancing the Three Main Phases of Global Outbreak Preparedness

Highlights:

This report focuses on epidemiology, research and development, current treatment and diagnostics and global response to selected pandemics of the past decade (2009-2020). The report discusses lessons learned from previous outbreaks in terms of policies and measures of prevention and control.

Report Includes:

  • An overview of the pandemic outbreaks occurred over the last decade (2010-2020)
  • Discussion of several serious epidemiological outbreaks, their socioeconomic impact, R&D efforts, treatment and diagnostics, clinical trial landscape, and regulatory and reimbursement landscape
  • Data corresponding to number of confirmed cases and reported deaths (globally and country wise) due to various pandemics, including novel coronavirus disease (COVID-19), SARS, MERS, HIV/AIDS, H1N1, Ebola virus etc.
  • Correlation of coronavirus (Covid-19) outbreak to previous epidemiological outbreaks in terms of policies and measures of prevention and control, and the lessons learned thereafter
  • Insight into key scientific breakthroughs and pipeline products targeting infectious disease treatments, including the novel coronavirus disease and its antibody-based clinical program (antibody to MERS-CoV infection)

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Introduction to Pandemics

  • Pathogenic Microbes and Infectious Diseases: 1973-2019
  • Factors Contributing to the Emergence of Infectious Diseases
    • Human Demographics and Behavior
    • Technology
    • The Role of Needles
    • Economic Development and Land Use
    • International Travel
    • Microbial Adaptation
    • Antibiotic Development
  • Classifying Viral Outbreaks, Epidemics and Pandemics
  • Current and Potential Epidemics with Pandemic Potential
  • Current and Potential Pandemics
  • Current Technologies for Addressing Potential Pandemic Threats
  • Biological Weapons for Terrorism
  • The Next Pandemic
  • Types of Zoonotic Viruses
  • A Brief History of Global Pandemics
    • Bubonic Plague (1300 to the Present)
    • Cholera (1916-1966)
    • The Spanish Influenza Pandemic (1918)
    • Asian Flu Pandemic (1957-1958)
    • HIV/AIDS Pandemic (1980 to the Present)
    • Influenza A-H1N1 (2009 to the Present)
    • Malaria (2700 BC to the Present)
    • Severe Acute Respiratory Syndrome (SARS) (2002-2003)
    • Tuberculosis (4000 BC to the Present)
  • Treatments for Infectious Diseases
    • Prevention
    • Vaccination
    • Pharmaceutical Treatments

Chapter 3: H1N1 Influenza (Swine Influenza)

  • Etiology
  • Epidemiology
  • Pathophysiology
  • Types of Influenza Viruses
    • Influenza Virus A
    • Influenza Virus B
    • Influenza Virus C
  • Diagnosis and Evaluation
    • Real-Time Polymerase Chain Reaction
    • Nucleotide Sequencing
    • Phylogenetic Analysis
  • Treatment and Management
    • Prevention of Swine to Human Viral Transmission
    • Prevention of Human-to-Human Transmission
    • Vaccines
    • Antiviral Treatments
  • The WHO and Containment for Pandemic Influenza
  • International Influenza Vaccine Stockpile Orders
  • Pre-pandemic Vaccination
    • Biomedical Advanced Research and Development Authority (BARDA)
  • Antiviral Resistance
  • Recreated Viruses
  • Immaterialized Market Risk
  • Media Coverage and Vaccinations
  • Pandemic Preparedness Plans
    • United States
    • Japan
    • China
    • Brazil
    • United Kingdom

Chapter 4: Ebola Virus Disease

  • Etiology
  • Epidemiology
  • Clinical Manifestations
  • Diagnosis
  • Treatment/Management
    • Supportive Care
    • Therapeutics
    • Vaccines and Prevention

Chapter 5: Middle East Respiratory Syndrome

  • Etiology
  • Epidemiology
    • Geographical Distribution
    • Sources of Infection
    • Risk Factors and Transmission
  • Pathophysiology
  • Clinical Features
  • Diagnosis
    • Molecular Diagnostics
    • Serological Assays
  • Treatment and Management
    • Antiviral Agents
    • Convalescent Plasma
    • Antibiotic Therapy
    • Intensive Care Management
    • New Treatments
  • Prevention
    • Advances in Vaccine Development
  • Priorities: MERS Research, Surveillance, Management, and Control
    • Establishing a One Health Global Consortium
    • Priority Studies at the Animal-Human-Environmental Interface
    • Priority Studies in Human Populations
    • Priority Studies for Vaccines, Therapeutics, and Rapid Diagnostics

Chapter 6: Coronavirus Disease 2019 (SARS-CoV-2)

  • Symptoms of COVID-19
  • COVID-19 Progression
  • Incubation Period
  • Epidemiology
    • Case Fatality Rate (CFR)
    • Global Confirmed Cases and Confirmed Deaths Due to COVID-19
  • COVID-19 Research and Development
  • Diagnostics and Medtech
  • The Need to Reinvent Ventilators
  • Clinical Trials on COVID-19

Chapter 7: Lessons Learned from History

  • Maintaining Essential Healthcare Services
  • Access to Prevention, Safety Measures, Testing and Treatment
  • Quarantine and Isolation
  • International Efforts to Strengthen the Global Outbreak Response System
    • Africa Centers for Disease Control and Prevention
    • Coalition for Epidemic Preparedness Innovations
    • European Medical Corps
    • Regional Disease Surveillance Systems Enhancement Program
    • The WHO Global Health Emergency Workforce
    • The WHO R&D Blueprint
    • World Bank Pandemic Emergency Financing Facility

Chapter 8: Appendix

  • Acronyms
Back to Top
전화 문의
F A Q